Observational studyBMC nephrology2026
Roxadustat induced fetal hemoglobin in anemic CKD patients: a dual-center real-world observational cohort study.
Observational study in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInduction of fetal hemoglobin (HbF) expression is a promising therapeutic approach for hemoglobinopathies. HbF is primarily regulated by hypoxia-inducible factor (HIF). Roxadustat, an oral HIF prolyl hydroxylase inhibitor (HIF-PHI), is utilized in the treatment of chronic kidney disease (CKD) patients with anemia. Its capacity to induce HbF has been demonstrated in cell and animal models, but not in humans.
methodsIn this dual-center, prospective, real-world, non-randomized observational cohort study, we initially enrolled 85 anemic CKD patients receiving distinct anti-anemia treatments. Following post hoc exclusion of participants with insufficient follow-up data, we analyzed the data of 52 patients, comprising those in the oral Roxadustat group (n = 27) and the subcutaneous erythropoiesis-stimulating agent (ESA) group (n = 25). HbF levels were monitored every four weeks by measuring the percentage of HbF-positive red blood cells (F-cells) and mean corpuscular fetal hemoglobin (MCHbF).
resultsRoxadustat administration showed progressive elevation of HbF levels, however, the ESA group exhibited only minor nonprogressive HbF fluctuations throughout the observation period. Significant differences in the increase of F-cells percentage and MCHbF between the two groups were observed at week 4 and amplified at week 8 and 12. Only one patient in the Roxadustat group exhibited clinically significant hypothyroidism requiring levothyroxine replacement. Safety monitoring was limited to clinically evident events reported during routine visits; consequently, subclinical abnormalities or mild adverse events were not systematically documented.
conclusionOur study suggested that Roxadustat has the potential to induce HbF expression in anemic CKD patients. STUDY REGISTRATION: The study was registered retrospectively in the Chinese Clinical Trial Registry (ChiCTR, https://www.chictr.org.cn) under the identifier ChiCTR2500096786 on February 6, 2025.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.